Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 13/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.38 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.38 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182132 | 0.94 | NMBR (0.45) | NMBRSLC6A9SOAT2ACAT1SOAT1 | |
| SCHEMBL6183621 | 0.92 | NMBR (0.46) | NMBRSOAT2ACAT1SOAT1PTGES | |
| SCHEMBL6183034 | 0.90 | NMBR (0.48) | NMBRSOAT2ACAT1SOAT1PTGES | |
| SCHEMBL6805340 | 0.85 | NMBR (0.48) | NMBRSOAT2ACAT1SOAT1 | |
| SCHEMBL6186309 | 0.84 | NMBR (0.51) | NMBRSOAT2ACAT1SOAT1 | |
| SCHEMBL6804233 | 0.83 | NMBR (0.52) | NMBRSOAT2ACAT1SOAT1 | |
| SCHEMBL6185673 | 0.83 | NMBR (0.45) | NMBRSOAT2ACAT1SOAT1PTGES | |
| SCHEMBL6803553 | 0.83 | NMBR (0.50) | NMBRSOAT2ACAT1SOAT1 | |
| SCHEMBL6218992 | 0.82 | NMBR (0.46) | NMBRSOAT2ACAT1SOAT1 | |
| SCHEMBL6808025 | 0.80 | NMBR (0.44) | NMBRSOAT2ACAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | claimed |
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | NMBR 211/4885SLC6A9 1049/4885SOAT2 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.